Press releases

Oxford BioMedica plc Management and Board change

--Appointment of new Chief Financial Officer and Company Secretary --

Oxford, UK – 10 February 2012: Oxford BioMedica (“Oxford BioMedica” or “the Company”) (LSE: OXB), the leading gene-based biopharmaceutical company, today announces that Andrew Wood, Chief Financial Officer, has stepped down from the Board of Oxford BioMedica.  Tim Watts has been appointed to the Board as Chief Financial Officer and Company Secretary of Oxford BioMedica with immediate effect.  Andrew will continue as an employee of the Company for the time being to ensure the smooth transition of the role.

Tim is a senior financial executive with over 30 years’ experience in leading multinational and entrepreneurial businesses.  He was most recently Chief Financial Officer at Archimedes Pharma Ltd., an international specialty pharmaceutical company.  Tim qualified as a chartered accountant, beginning his career with Coopers & Lybrand before moving to H J Heinz, the food producer.  In 1985 Tim joined ICI, initially in the corporate headquarters and from 1990 in the pharmaceuticals division, eventually rising to be Finance Director of the Zeneca Pharmaceuticals business.  Following the merger of Astra and Zeneca, Tim became Group Financial Controller of AstraZeneca PLC in 2001.  In 2007 he left AstraZeneca to become Chief Financial Officer at Archimedes Pharma.  Tim has a proven track record in the industry, including managing corporate transactions, M&A activity, fundraising and strategic implementation.

John Dawson, Chief Executive Officer of Oxford BioMedica, said: “We thank Andrew for his substantial contribution to Oxford BioMedica since its IPO in 1996.  His commitment to the Company has been invaluable and we wish him well for the future.  I would like to welcome Tim to the executive management team and am confident that his expertise will support Oxford BioMedica’s strategy to secure corporate and commercial success.”

There is no other information to be disclosed under Paragraph 9.6.13 R of the Listing Rules.


Notes to editors

About Oxford BioMedica

Oxford BioMedica (LSE:OXB) is a leading gene and cell therapy group focused on developing life changing treatments for serious diseases. Oxford BioMedica and its subsidiaries (the "Group") have built a sector leading lentiviral vector delivery platform (LentiVector®), which the Group leverages to develop in vivo and ex vivo products both in-house and with partners. The Group has created a valuable proprietary portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology and CNS disorders. The Group has also entered into a number of partnerships, including with Novartis, Bioverativ, Sanofi, Axovant, Orchard Therapeutics, Boehringer Ingelheim/UK Cystic Fibrosis Gene Therapy Consortium/Imperial Innovations, GC LabCell and Immune Design, through which it has long-term economic interests in other potential gene and cell therapy products. Oxford BioMedica is based across several locations in Oxfordshire, UK and employs more than 320 people. Further information is available at

For further information please contact

Oxford BioMedica plc

John Dawson, Chief Executive Officer
Stuart Paynter, Chief Financial Officer
Sarah MacLeod, Head of Communications
Tel: +44 (0)1865 783 000

Financial and corporate communications enquiries:
Consilium Strategic Communications
Mary-Jane Elliott/Matthew Neal/Olivia Manser/Laura Thornton
Tel: +44 (0)20 3709 5700